Evidence map›Paper›PMID 33507475›Full record

ArticleMolecular biology reports2021

Clinical, radiological and computational studies on two novel GNPTG variants causing mucolipidosis III gamma phenotypes with varying severity.

Mustafa Doğan, Recep Eröz, Kerem Terali, Alper Gezdirici, Semih Bolu

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in Molecular biology reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 49% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 2 countries.

Mustafa DoğanDepartment of Medical Genetics, Malatya Turgut Ozal University Training and Research Hospital, Malatya, Turkey. mustafadogan81@yahoo.com.ORCID http://orcid.org/0000-0003-0464-6565
Recep ErözDepartment of Medical Genetics, Faculty of Medicine, Düzce University, Düzce, Turkey.
Kerem TeraliDepartment of Medical Biochemistry, Faculty of Medicine, Near East University, Nicosia, Cyprus.ORCID https://orcid.org/0000-0002-9964-6383
Alper GezdiriciDepartment of Medical Genetics, Basaksehir Cam and Sakura City Hospital, 34480, Istanbul, Turkey.ORCID https://orcid.org/0000-0002-2432-9279
Semih BoluDepartment of Pediatric Endocrinology, Adıyaman Training and Research Hospital, Adıyaman, Turkey.
Adıyaman University · TRDüzce Üniversitesi · TRIstanbul Metropolitan Municipality · TRMalatya Turgut Özal Üniversitesi · TRNear East University · CY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mucolipidosis III gamma (ML III γ) is a slowly progressive disorder that affects multiple parts of the body such as the skeleton, joints, and connective tissue structures. It is caused by pathogenic variants in the GNPTG gene that provides instructions for producing the γ subunit of GlcNAc-1-phosphotransferase. In this study we aim to characterize clinical findings and biological insights on two novel GNPTG variants causing ML III γ phenotypes with varying severity. We report on two siblings with ML III γ bearing the previously undescribed c.477C > G (p.Y159*) nonsense variant in a homozygous state as well as a patient with ML III γ bearing the novel c.110 + 19_111-17del variant in a homozygous state. These variants were revealed by whole-exome sequencing and Sanger sequencing, respectively. Their parents, who are heterozygotes for the same mutation, are healthy. The clinical and radiographic presentation of ML III γ in our patients who had c.477C > G (p.Y159*) variant is consistent with a relatively severe form of the disease, which is further supported by a working three-dimensional model of the GlcNAc-1-phosphotransferase γ subunit. On the other hand, it is seen that our patient who carries the c.110 + 19_111-17del variant has a milder phenotype. Our findings help broaden the spectrum of GNPTG variants causing ML III γ and offer structural and mechanistic insights into loss of GlcNAc-1-phosphotransferase γ subunit function.

Indexed as

Genetic Predisposition to DiseaseCodon, NonsenseExome SequencingFemaleHomozygoteHumansJointsMaleMucolipidosesPhenotypeSeverity of Illness IndexSiblingsSkeletonTransferases (Other Substituted Phosphate Groups)Codon, NonsenseGNPTG protein, humanTransferases (Other Substituted Phosphate Groups)GlcNAc-1-phosphotransferaseGNPTGLysosomal storage disorderMucolipidosis III gamma

Identifiers

PMID33507475
OpenAlexW3121894990

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.